This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Mersana Therapeutics Stock (NASDAQ:MRSN) Get Mersana Therapeutics alerts:Sign Up Key Stats Today's Range$28.78▼$30.3950-Day Range$27.47▼$29.1052-Week Range$5.21▼$30.39Volume712,400 shsAverage Volume112,909 shsMarket Capitalization$145.37 millionP/E RatioN/ADividend YieldN/APrice Target$30.75Consensus RatingReduce Company Overview Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Since its founding in 2003, Mersana has leveraged its proprietary Fleximer® platform to engineer next-generation ADCs that aim to improve the therapeutic index by enhancing drug delivery to tumor cells while minimizing systemic toxicity. The company’s research efforts are centered on creating highly potent payloads linked to antibodies that selectively target tumor-associated antigens. The Fleximer platform enables site-specific conjugation of multiple payload molecules, offering adjustable drug-to-antibody ratios and controlled release characteristics. Mersana’s pipeline includes several clinical and preclinical candidates. Among the lead programs is XMT-1536 (UpRi), which targets the sodium-dependent phosphate transporter NaPi2b and is being evaluated in patients with platinum-resistant ovarian cancer. Another notable program, XMT-1592, targets mesothelin-expressing solid tumors such as non-small cell lung cancer and mesothelioma. These programs underscore the company’s commitment to addressing high-unmet-need oncology indications through precision medicine approaches. In addition to its internal development efforts, Mersana has entered into strategic collaborations with several global biopharmaceutical partners to advance its ADC candidates. These alliances support clinical development, manufacturing scale-up and potential co-commercialization, extending the company’s reach into key markets in North America, Europe and Asia. Through these partnerships, Mersana seeks to leverage complementary expertise and resources to accelerate the translation of its novel therapies from the laboratory to the clinic. Leadership at Mersana is headed by President and Chief Executive Officer Robert Mulroy, who brings extensive experience in oncology drug development and life-science management. Under his guidance, the company has grown its research team and infrastructure to support a robust pipeline of targeted therapeutics. With a scientific advisory board composed of oncology and antibody engineering experts, Mersana continues to explore new indications and refine its ADC technologies in pursuit of improved outcomes for patients with cancer.AI Generated. May Contain Errors. Read More Mersana Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreMRSN MarketRank™: 0.22302834878 of 5 starsMersana Therapeutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 882nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingReduce Consensus RatingMersana Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Mersana Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMersana Therapeutics has received no research coverage in the past 90 days.Read more about Mersana Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MRSN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for MRSN on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRSN Stock News HeadlinesHow The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN)January 9, 2026 | finance.yahoo.comMersana Therapeutics completes merger and delists from NasdaqJanuary 6, 2026 | msn.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 25 at 1:00 AM | Behind the Markets (Ad)Day One Biopharmaceuticals, Inc.: Day One Completes Acquisition of Mersana TherapeuticsJanuary 6, 2026 | finanznachrichten.deShareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 16, 2025 | prnewswire.comMersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSNDecember 12, 2025 | prnewswire.comHalper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their RightsNovember 18, 2025 | marketwatch.comHalper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their RightsNovember 18, 2025 | marketwatch.comSee More Headlines MRSN Stock Analysis - Frequently Asked Questions How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Friday, November, 14th. The company reported ($1.51) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.07. The firm earned $11.01 million during the quarter, compared to analyst estimates of $14.20 million. When did Mersana Therapeutics' stock split? Mersana Therapeutics shares reverse split on Friday, July 25th 2025.The 1-25 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Bank of America (BAC), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and ImmunoGen (IMGN). Company Calendar Last Earnings11/14/2025Today10/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MRSN CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees150Year Founded2005Price Target and Rating Average Price Target for Mersana Therapeutics$30.75 High Price Target$30.75 Low Price Target$30.75 Potential Upside/Downside+5.7%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($13.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.19 million Net Margins-211.21% Pretax Margin-211.21% Return on EquityN/A Return on Assets-65.42% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.39 Sales & Book Value Annual Sales$33.18 million Price / Sales4.38 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-15.15Miscellaneous Outstanding Shares4,999,000Free Float4,349,000Market Cap$145.37 million OptionableOptionable Beta0.44 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MRSN) was last updated on 1/6/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
